FY2026 EPS Estimates for Journey Medical Cut by Roth Capital

Journey Medical Co. (NASDAQ:DERM) – Investment analysts at Roth Capital decreased their FY2026 earnings per share estimates for shares of Journey Medical in a research note issued to investors on Thursday, May 15th. Roth Capital analyst J. Wittes now anticipates that the company will post earnings of $2.02 per share for the year, down from their previous estimate of $2.18. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. Roth Capital also issued estimates for Journey Medical’s FY2027 earnings at $3.05 EPS, FY2028 earnings at $4.75 EPS and FY2029 earnings at $5.33 EPS.

Other equities research analysts have also issued reports about the company. Alliance Global Partners reiterated a “buy” rating on shares of Journey Medical in a research note on Thursday, March 27th. Industrial Alliance Securities set a $10.50 price target on Journey Medical in a research report on Thursday, March 27th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $9.88.

Journey Medical Price Performance

NASDAQ:DERM opened at $6.93 on Friday. Journey Medical has a 12 month low of $3.20 and a 12 month high of $8.24. The stock has a 50 day moving average of $6.44 and a two-hundred day moving average of $5.42. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 1.81. The firm has a market cap of $160.11 million, a P/E ratio of -7.37 and a beta of 0.86.

Journey Medical (NASDAQ:DERM) last posted its quarterly earnings data on Wednesday, May 14th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.06. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%. The company had revenue of $13.14 million during the quarter, compared to analyst estimates of $12.05 million.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Kovitz Investment Group Partners LLC grew its position in Journey Medical by 112.9% in the fourth quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock worth $97,000 after acquiring an additional 13,105 shares during the period. Titleist Asset Management LLC lifted its stake in Journey Medical by 18.3% during the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company’s stock worth $76,000 after purchasing an additional 2,000 shares in the last quarter. Pale Fire Capital SE acquired a new stake in shares of Journey Medical in the first quarter valued at $161,000. Cambridge Investment Research Advisors Inc. raised its stake in shares of Journey Medical by 3.0% in the first quarter. Cambridge Investment Research Advisors Inc. now owns 338,050 shares of the company’s stock valued at $1,994,000 after acquiring an additional 9,938 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Journey Medical in the fourth quarter valued at $174,000. 7.25% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, CEO Claude Maraoui sold 18,147 shares of the company’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $5.13, for a total value of $93,094.11. Following the completion of the sale, the chief executive officer now directly owns 2,092,874 shares in the company, valued at $10,736,443.62. This represents a 0.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders sold 113,522 shares of company stock worth $589,229 over the last ninety days. Corporate insiders own 13.16% of the company’s stock.

About Journey Medical

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.